After a weak first half, the drug and biotech sector has recovered in the past 2-3 months, with most large drugmakers signing drug pricing agreements with the Trump administration. After a cautious ...
Johnson & Johnson is rated a buy, with accelerating revenue and earnings growth driven by TREMFYA, CARVYKTI, and robust MedTech innovation. JNJ's portfolio reshaping (divesting Orthopaedics and ...
The Healthy on MSN
What I wish I’d known about cataract surgery: A doctor details what patients should know about a common procedure
What are the signs that show I need cataract surgery? “There are several key signs that someone may need cataract surgery,” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback